Sign in to view content

Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial

Jason Hsu, MD

Video
Published 2021

Related

Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study
Eric W Schneider, MD
Updates from the Field
2025
Beyond Complement: A Novel FAS Inhibition Approach for Neuroprotection in GA
Vaidehi S. Dedania, MD
Updates from the Field
2024
Association of Metformin Use and New-Onset of ICD-Coding of Geographic Atrophy
Dimitra Skondra, MD,PhD
Annual Meeting Talks
2024

Category: AMD-Non-Neovascular

See more